Back to Search
MAURIZIO ZANGARI, MD
MD
Hematology & Oncology Physician
NPI: 1568476901IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
E-0366(AR)
Education
OTHER
Class of 1980
Research & Publications (20)
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
PMID 18371114·Br J Haematol·2008
3-trial
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
PMID 17890944·Blood Coagul Fibrinolysis·2007
2-rct
Hemostatic dysfunction in paraproteinemias and amyloidosis.
PMID 17525891·Semin Thromb Hemost·2007
6-review
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
PMID 17546639·Am J Hematol·2007
4-observational
Anticoagulation regimens for thalidomide and lenalidomide.
PMID 17099621·Clin Adv Hematol Oncol·2006
8-other
Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
PMID 17168661·Curr Pharm Biotechnol·2006
6-review
Response to bortezomib and activation of osteoblasts in multiple myeloma.
PMID 17026821·Clin Lymphoma Myeloma·2006
6-review
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
PMID 16173965·Br J Haematol·2005
4-observational
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
PMID 15327525·Br J Haematol·2004
3-trial
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
PMID 14734456·Clin Cancer Res·2004
3-trial
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
PMID 12837152·Clin Lymphoma·2003
8-other
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
PMID 12149193·Blood·2002
3-trial
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
PMID 11943931·Blood Coagul Fibrinolysis·2002
3-trial
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
PMID 11520815·Blood·2001
3-trial
Bleeding disorders associated with cancer dysproteinemias.
PMID 19377931·Cancer Treat Res·2009
6-review
Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy.
PMID 19455356·Support Care Cancer·2010
3-trial
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
PMID 19458357·Blood·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4301 W MARKHAM ST
LITTLE ROCK, AR 72205 - Phone
- (501) 526-2873
Quick Facts
- NPI
- 1568476901
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile